Research Center for Biochemistry and Nutrition in Metabolic Diseases, Kashan University of Medical Sciences, Kashan, Iran.
Health Policy Research Center, Institute of Health, Student Research Committee, Shiraz University of Medical Sciences, Shiraz, Iran.
Curr Pharm Des. 2018;24(23):2729-2742. doi: 10.2174/1381612824666180406104516.
Oxidative stress and inflammation are key parameters in developing metabolic disorders. Hence, antioxidant intake might be an appropriate approach. Several studies have evaluated the effect of coenzyme Q10 (CoQ10) supplementation on lipid profile among patients with metabolic diseases, though findings are controversial. The aim of this systematic review and meta-analysis was to determine the effects of CoQ10 supplementation on lipid profile in patients with metabolic disorders.
We searched PubMed, EMBASE, Web of Science and Cochrane Library databases until July 2017. Prospective clinical trials were selected assessing the effect of CoQ10 supplementation on different biomarkers. Two reviewers independently assessed the eligibility of studies, extracted data, and evaluated the risk of bias of included studies. A fixed- or random-effects model was used to pool the data, which expressed as a standardized mean difference with 95% confidence interval. Heterogeneity was measured using a Q-test and with I2 statistics.
A total of twenty-one controlled trials (514 patients and 525 controls) were included. The meta-analysis indicated a significant reduction in serum triglycerides levels (SMD -0.28; 95% CI, -0.56, -0.005). CoQ10 supplementation also decreased total-cholesterol (SMD -0.07; 95% CI, -0.45, 0.31), increased LDL- (SMD 0.04; 95% CI, -0.27, 0.36), and HDL-cholesterol levels (SMD 0.10; 95% CI, -0.32, 0.51), not statistically significant.
CoQ10 supplementation may significantly reduce serum triglycerides levels, and help to improve lipid profiles in patients with metabolic disorders. Additional prospective studies are recommended using higher supplementation doses and longer intervention period.
氧化应激和炎症是代谢紊乱发展的关键参数。因此，抗氧化剂的摄入可能是一种合适的方法。已有多项研究评估了辅酶 Q10（CoQ10）补充剂对代谢疾病患者血脂谱的影响，但结果存在争议。本系统评价和荟萃分析的目的是确定 CoQ10 补充剂对代谢紊乱患者血脂谱的影响。
我们检索了 PubMed、EMBASE、Web of Science 和 Cochrane 图书馆数据库，检索时间截至 2017 年 7 月。选择评估 CoQ10 补充剂对不同生物标志物影响的前瞻性临床试验。两名评审员独立评估研究的合格性、提取数据，并评估纳入研究的偏倚风险。使用固定或随机效应模型对数据进行汇总，以标准化均数差（95%置信区间）表示。使用 Q 检验和 I2 统计量来衡量异质性。
共纳入 21 项对照试验（514 例患者和 525 例对照）。荟萃分析表明，血清甘油三酯水平显著降低（SMD -0.28；95%CI，-0.56，-0.005）。CoQ10 补充剂还降低了总胆固醇（SMD -0.07；95%CI，-0.45，0.31），增加了 LDL-（SMD 0.04；95%CI，-0.27，0.36）和 HDL-胆固醇水平（SMD 0.10；95%CI，-0.32，0.51），但无统计学意义。
CoQ10 补充剂可能显著降低代谢紊乱患者的血清甘油三酯水平，有助于改善其血脂谱。建议开展更多前瞻性研究，采用更高的补充剂量和更长的干预时间。
